<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01381484</url>
  </required_header>
  <id_info>
    <org_study_id>Svarothai</org_study_id>
    <nct_id>NCT01381484</nct_id>
  </id_info>
  <brief_title>Argireline in Treatment of Periorbital Wrinkles</brief_title>
  <official_title>Efficacy and Safety of Topical Argireline in the Treatment of Periorbital Wrinkles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pacific Health Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether La Jolie gel is effective in the treatment
      of periorbital wrinkles.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Argireline has mechanism of action that significantly inhibited neurotransmitter release with
      a potency similar to that of BoNTA. Inhibition of neurotransmitter release was due to the
      interference of the hexapeptide with the formation and/or stability of SNARE complex.
      Notably, this peptide did not exhibit in vivo oral toxicity nor primary irritation at high
      doses. These findings demonstrate that Argireline is a anti-wrinkle peptide that emulates the
      action of currently used BoNTs.

      In vivo study, Topical Argireline 10% is applied on lateral preorbital area twice daily for
      30 days. The result demonstrates a significant anti-wrinkle activity by decreased skin
      wrinkle 30%. These findings demonstrate a significant anti-wrinkle activity for Argireline,
      in agreement with its in vitro and cellular activities. Topical Argireline represents a
      bio-safe alternative to BoNTs in anti-wrinkle therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>3 months</time_frame>
    <description>Objective evaluation
Noninvasive measurement by skin bioengineering technique e.g. visioscan, corneometer, cutometer
Comparative photographic evaluation by certified dermatologists
Subjective evaluation
Patient Self assessment satifaction review</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>3 months</time_frame>
    <description>Number of participants with adverse events Categorized adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Wrinkles</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group received placebo gel and requested to apply periorbital area and over the face for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group received La Jolie Gel and requested to apply periorbital area and over the face for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10% Argireline</intervention_name>
    <description>10% Argireline (La jolie gel®, Pacific health care, Thailand) were instructed to apply the gel over the face and periorbital area twice daily for a period of 3 months.</description>
    <arm_group_label>Study group</arm_group_label>
    <other_name>10% Argireline (La jolie gel®)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy woman at 35-45 years old

          -  Presence of periorbital wrinkles

        Exclusion Criteria:

          -  Pregnancy

          -  Nursing

          -  Keloids /scar at periorbital area

          -  pre-treatment with topical periorbital products within 1 month

          -  Botulinum toxin A injection,facial plastic surgery within 1 year

          -  Allergic to active ingredients including acetyl hexapeptide-3 Argireline®, sodium
             hyaluronate,adenosine,arbutin,fucus vesiculosus)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Supenya varothai, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University</name>
      <address>
        <city>Bangkoknoi</city>
        <state>Bangkok</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Blanes-Mira C, Clemente J, Jodas G, Gil A, Fernández-Ballester G, Ponsati B, Gutierrez L, Pérez-Payá E, Ferrer-Montiel A. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002 Oct;24(5):303-10. doi: 10.1046/j.1467-2494.2002.00153.x.</citation>
    <PMID>18498523</PMID>
  </reference>
  <reference>
    <citation>Tokiwa Y, Kitagawa M, Raku T, Yanagitani S, Yoshino K. Enzymatic synthesis of arbutin undecylenic acid ester and its inhibitory effect on melanin synthesis. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3105-8. Epub 2007 Mar 16.</citation>
    <PMID>17418566</PMID>
  </reference>
  <results_reference>
    <citation>Farage MA, Miller KW, Elsner P, Maibach HI. Intrinsic and extrinsic factors in skin ageing: a review. Int J Cosmet Sci. 2008 Apr;30(2):87-95. doi: 10.1111/j.1468-2494.2007.00415.x. Review.</citation>
    <PMID>18377617</PMID>
  </results_reference>
  <results_reference>
    <citation>Klein AW. Complications, adverse reactions, and insights with the use of botulinum toxin. Dermatol Surg. 2003 May;29(5):549-56; discussion 556. Review.</citation>
    <PMID>12752527</PMID>
  </results_reference>
  <results_reference>
    <citation>Brown MB, Jones SA. Hyaluronic acid: a unique topical vehicle for the localized delivery of drugs to the skin. J Eur Acad Dermatol Venereol. 2005 May;19(3):308-18. Review.</citation>
    <PMID>15857456</PMID>
  </results_reference>
  <results_reference>
    <citation>Abella ML. Evaluation of anti-wrinkle efficacy of adenosine-containing products using the FOITS technique. Int J Cosmet Sci. 2006 Dec;28(6):447-51. doi: 10.1111/j.1467-2494.2006.00349.x.</citation>
    <PMID>18489289</PMID>
  </results_reference>
  <results_reference>
    <citation>Senni K, Gueniche F, Foucault-Bertaud A, Igondjo-Tchen S, Fioretti F, Colliec-Jouault S, Durand P, Guezennec J, Godeau G, Letourneur D. Fucoidan a sulfated polysaccharide from brown algae is a potent modulator of connective tissue proteolysis. Arch Biochem Biophys. 2006 Jan 1;445(1):56-64. Epub 2005 Nov 28.</citation>
    <PMID>16364234</PMID>
  </results_reference>
  <results_reference>
    <citation>Narins RS, Brandt F, Leyden J, Lorenc ZP, Rubin M, Smith S. A randomized, double-blind, multicenter comparison of the efficacy and tolerability of Restylane versus Zyplast for the correction of nasolabial folds. Dermatol Surg. 2003 Jun;29(6):588-95.</citation>
    <PMID>12786700</PMID>
  </results_reference>
  <results_reference>
    <citation>Rohrich RJ. The increasing popularity of cosmetic surgery procedures: a look at statistics in plastic surgery. Plast Reconstr Surg. 2000 Nov;106(6):1363-5.</citation>
    <PMID>11083570</PMID>
  </results_reference>
  <results_reference>
    <citation>Manaloto RM, Alster TS. Periorbital rejuvenation: a review of dermatologic treatments. Dermatol Surg. 1999 Jan;25(1):1-9. Review.</citation>
    <PMID>9935084</PMID>
  </results_reference>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2011</study_first_submitted>
  <study_first_submitted_qc>June 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <last_update_submitted>June 23, 2011</last_update_submitted>
  <last_update_submitted_qc>June 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Department of dermatology</name_title>
    <organization>Mahidol university</organization>
  </responsible_party>
  <keyword>Periorbital wrinkles</keyword>
  <keyword>Efficacy and safety</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

